TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Kristina W W ThielEric J DevorVirginia L FiliaciDavid G MutchKatherine MoxleyAngeles A SecordKrishnansu S TewariMegan E McDonaldCara A MathewsCasey CosgroveSummer DewdneyCarol AghajanianMegan I SamuelsonHeather A LankesRobert A SoslowKimberly Kay LesliePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
identifies a specific, high-risk tumor genotype/phenotype for which bevacizumab is particularly beneficial in improving outcomes when combined with chemotherapy.